Biotech · Private company
Alcresta Therapeutics, Inc.
Track this companyFree. Adds Alcresta Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials55 recruiting or active
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Clinical trials5
- Evaluating RELiZORB Use for the Treatment of Feeding Intolerance in Adults With Moderate to Severe Acute PancreatitisPHASE4 · ENROLLING_BY_INVITATION · started Dec 8, 2025ClinicalTrials.gov NCT07583342 · fetched Nov 12, 2026
- Evaluating the Utility of RELiZORB™ for Treating Feeding Intolerance in Critically Ill Adults With Multi-Organ FailureNA · ACTIVE_NOT_RECRUITING · started May 7, 2025ClinicalTrials.gov NCT05710315 · fetched Nov 12, 2026
- Evaluating the Efficacy of RELiZORB in Managing Exocrine Pancreatic Insufficiency in Tube-fed Pancreatitis PatientsPHASE3 · RECRUITING · started Mar 28, 2025ClinicalTrials.gov NCT06691893 · fetched Nov 12, 2026
- A 90 Day Observational Study as an Extension to the Phase 3,Open Labeled Exploratory Study of RELiZORBENROLLING_BY_INVITATION · started Sep 29, 2022ClinicalTrials.gov NCT05635747 · fetched Nov 12, 2026
- A 90 Day, Phase 3,Open Labeled Exploratory Study of RELiZORBNA · RECRUITING · started Nov 21, 2018ClinicalTrials.gov NCT03530852 · fetched Nov 12, 2026